Victory Capital Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-11,788
| Closed | -$35.8K | – | 2539 |
|
|
2024
Q4 | $35.8K | Sell |
11,788
-285
| -2% | -$1.24K | ﹤0.01% | 2418 |
|
|
2024
Q3 | $62.7K | Sell |
12,073
-236
| -2% | -$1.17K | ﹤0.01% | 2373 |
|
|
2024
Q2 | $31.6K | Buy |
12,309
+1,908
| +18% | +$6.51K | ﹤0.01% | 2398 |
|
|
2024
Q1 | $51.2K | Sell |
10,401
-153
| -1% | -$906 | ﹤0.01% | 2376 |
|
|
2023
Q4 | $92.8K | Buy |
+10,554
| New | +$86.5K | ﹤0.01% | 2354 |
|
|
2023
Q3 | – | Sell |
-564,355
| Closed | -$14.3M | – | 2571 |
|
|
2023
Q2 | $14.3M | Sell |
564,355
-34,330
| -6% | -$1.07M | 0.02% | 904 |
|
|
2023
Q1 | $19.3M | Buy |
598,685
+567,555
| +1,823% | +$17.7M | 0.02% | 798 |
|
|
2022
Q4 | $575K | Sell |
31,130
-9,410
| -23% | -$215K | ﹤0.01% | 1960 |
|
|
2022
Q3 | $1.09M | Buy |
+40,540
| New | +$822K | ﹤0.01% | 1694 |
|
|
2021
Q4 | – | Sell |
-9,482
| Closed | -$264K | – | 2862 |
|
|
2021
Q3 | $264K | Sell |
9,482
-436
| -4% | -$12.4K | ﹤0.01% | 2425 |
|
|
2021
Q2 | $294K | Sell |
9,918
-284
| -3% | -$8.19K | ﹤0.01% | 2424 |
|
|
2021
Q1 | $285K | Buy |
10,202
+391
| +4% | +$10.8K | ﹤0.01% | 2415 |
|
|
2020
Q4 | $278K | Buy |
9,811
+483
| +5% | +$12.5K | ﹤0.01% | 2302 |
|
|
2020
Q3 | $235K | Buy |
+9,328
| New | +$245K | ﹤0.01% | 2246 |
|
|
2020
Q2 | – | Sell |
-15,966
| Closed | -$236K | – | 3366 |
|
|
2020
Q1 | $236K | Buy |
15,966
+6,119
| +62% | +$127K | ﹤0.01% | 2294 |
|
|
2019
Q4 | $160K | Buy |
9,847
+3,508
| +55% | +$54.4K | ﹤0.01% | 2376 |
|
|
2019
Q3 | $82K | Buy |
+6,339
| New | +$77.6K | ﹤0.01% | 2501 |
|
|
2018
Q3 | – | Sell |
-59,245
| Closed | -$1.63M | – | 1904 |
|
|
2018
Q2 | $1.63M | Sell |
59,245
-3,300
| -5% | -$99.2K | ﹤0.01% | 1122 |
|
|
2018
Q1 | $1.93M | Buy |
62,545
+6,860
| +12% | +$221K | ﹤0.01% | 1079 |
|
|
2017
Q4 | $1.99M | Buy |
55,685
+20,970
| +60% | +$602K | ﹤0.01% | 1037 |
|
|
2017
Q3 | $956K | Sell |
34,715
-160
| -0.5% | -$3.88K | ﹤0.01% | 1221 |
|
|
2017
Q2 | $921K | Sell |
34,875
-650
| -2% | -$14.5K | ﹤0.01% | 1205 |
|
|
2017
Q1 | $739K | Buy |
+35,525
| New | +$730K | ﹤0.01% | 1235 |
|
Other funds holding RVNC
Victory Capital Management's RVNC Position: Q1 2025 in Review
Victory Capital Management sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 11,788 shares — an estimated $35.8K sold.
Victory Capital Management first reported a position in RVNC in Q1 2017 and held it in 23 quarters. The position peaked at $19.3M in Q1 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.
- Victory Capital Management reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
- Victory Capital Management sold 11,788 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $35.8K.
- Victory Capital Management first reported a position in Revance Therapeutics, Inc. in Q1 2017 and held it in 23 quarters.
- Victory Capital Management's Revance Therapeutics, Inc. position peaked at $19.3M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.
Based on Victory Capital Management's 13F filing for Q1 2025, filed 2 May 2025.